CHICAGO TRUST Co NA Buys 874 Shares of Elevance Health, Inc. (NYSE:ELV)

CHICAGO TRUST Co NA grew its stake in Elevance Health, Inc. (NYSE:ELV) by 110.2% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,667 shares of the company’s stock after purchasing an additional 874 shares during the period. CHICAGO TRUST Co NA’s holdings in Elevance Health were worth $867,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of ELV. New Mexico Educational Retirement Board grew its stake in shares of Elevance Health by 14.6% during the first quarter. New Mexico Educational Retirement Board now owns 14,146 shares of the company’s stock valued at $6,949,000 after buying an additional 1,800 shares during the last quarter. Blair William & Co. IL boosted its stake in shares of Elevance Health by 119.7% during the first quarter. Blair William & Co. IL now owns 12,134 shares of the company’s stock valued at $6,292,000 after purchasing an additional 6,610 shares during the period. AMI Investment Management Inc. bought a new position in shares of Elevance Health in the third quarter worth about $1,294,000. Artemis Investment Management LLP increased its stake in Elevance Health by 16.1% in the 1st quarter. Artemis Investment Management LLP now owns 83,757 shares of the company’s stock worth $43,422,000 after buying an additional 11,627 shares during the period. Finally, BDF Gestion bought a new stake in Elevance Health during the 2nd quarter valued at about $5,837,000. 89.24% of the stock is owned by institutional investors.

Insider Activity at Elevance Health

In other Elevance Health news, Director Robert L. Dixon, Jr. sold 305 shares of the firm’s stock in a transaction that occurred on Friday, July 19th. The stock was sold at an average price of $506.76, for a total value of $154,561.80. Following the sale, the director now directly owns 9,721 shares of the company’s stock, valued at approximately $4,926,213.96. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Elevance Health news, Director Robert L. Dixon, Jr. sold 305 shares of the company’s stock in a transaction on Friday, July 19th. The shares were sold at an average price of $506.76, for a total transaction of $154,561.80. Following the completion of the transaction, the director now directly owns 9,721 shares in the company, valued at approximately $4,926,213.96. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Ramiro G. Peru sold 753 shares of Elevance Health stock in a transaction dated Monday, August 5th. The shares were sold at an average price of $531.52, for a total transaction of $400,234.56. Following the completion of the sale, the director now owns 8,744 shares in the company, valued at approximately $4,647,610.88. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 35,058 shares of company stock worth $17,588,116 in the last 90 days. Corporate insiders own 0.35% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on ELV shares. Truist Financial raised their target price on shares of Elevance Health from $600.00 to $620.00 and gave the stock a “buy” rating in a research report on Monday, July 15th. Cantor Fitzgerald restated an “overweight” rating and set a $600.00 price objective on shares of Elevance Health in a report on Tuesday, October 1st. Stephens restated an “overweight” rating and issued a $615.00 price target on shares of Elevance Health in a report on Thursday, September 5th. Bank of America reiterated a “neutral” rating and issued a $530.00 price target (down from $646.00) on shares of Elevance Health in a research note on Thursday, July 18th. Finally, Barclays lifted their price objective on shares of Elevance Health from $611.00 to $622.00 and gave the stock an “overweight” rating in a research note on Thursday. One investment analyst has rated the stock with a hold rating, fourteen have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Elevance Health currently has a consensus rating of “Buy” and an average target price of $605.07.

Elevance Health Trading Up 2.0 %

Elevance Health stock opened at $501.88 on Friday. The firm has a market cap of $116.65 billion, a PE ratio of 18.97, a P/E/G ratio of 1.08 and a beta of 0.82. Elevance Health, Inc. has a 12 month low of $435.99 and a 12 month high of $567.26. The stock’s 50 day simple moving average is $531.94 and its two-hundred day simple moving average is $529.09. The company has a current ratio of 1.49, a quick ratio of 1.49 and a debt-to-equity ratio of 0.58.

Elevance Health (NYSE:ELV) last announced its quarterly earnings results on Wednesday, July 17th. The company reported $10.12 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $9.99 by $0.13. Elevance Health had a net margin of 3.89% and a return on equity of 20.64%. The firm had revenue of $43.22 billion for the quarter, compared to the consensus estimate of $42.99 billion. During the same period in the prior year, the firm posted $9.04 earnings per share. The firm’s quarterly revenue was down .4% compared to the same quarter last year. Analysts anticipate that Elevance Health, Inc. will post 37.26 earnings per share for the current year.

Elevance Health Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Wednesday, September 25th. Investors of record on Tuesday, September 10th were paid a $1.63 dividend. The ex-dividend date was Tuesday, September 10th. This represents a $6.52 annualized dividend and a dividend yield of 1.30%. Elevance Health’s dividend payout ratio is presently 24.64%.

Elevance Health Company Profile

Elevance Health, Inc, together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits.